according to the Hazardous Products Regulations



Carbidopa / Levodopa Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.1 09/30/2023 50110-00023 Date of first issue: 01/23/2015

SECTION 1. IDENTIFICATION

Product name : Carbidopa / Levodopa Formulation

Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Organon & Co.

Address : 30 Hudson Street, 33nd floor

Jersey City, New Jersey, U.S.A 07302

Telephone : 1-551-430-6000 Emergency telephone : 1-215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Acute toxicity (Oral) : Category 4

Reproductive toxicity : Category 2

Specific target organ toxicity : Ca

- repeated exposure (Oral)

: Category 1 (Central nervous system)

GHS label elements

Hazard pictograms





Signal Word : Danger

Hazard Statements : H302 Harmful if swallowed.

H361d Suspected of damaging the unborn child.

H372 Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product. P280 Wear protective gloves, protective clothing, eye protection

and face protection.

according to the Hazardous Products Regulations



Carbidopa / Levodopa Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.1 09/30/2023 50110-00023 Date of first issue: 01/23/2015

Response:

P301 + P312 + P330 IF SWALLOWED: Call a doctor if you feel

unwell. Rinse mouth.

P308 + P313 IF exposed or concerned: Get medical attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste

disposal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Levodopa	No data availa- ble	59-92-7	>= 60 - < 80 *
Carbidopa	No data availa- ble	38821-49-7	>= 10 - < 30 *
Cellulose	No data availa- ble	9004-34-6	>= 1 - < 5 *
Starch	Sago starch	9005-25-8	>= 1 - < 5 *
Magnesium stearate	Octadecanoic acid, magnesi- um salt (2:1)	557-04-0	>= 1 - < 5 *

Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention.
Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

according to the Hazardous Products Regulations



Carbidopa / Levodopa Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.1 09/30/2023 50110-00023 Date of first issue: 01/23/2015

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and

and effects, both acute and

Protection of first-aiders

delayed

Suspected of damaging the unborn child.

Causes damage to organs through prolonged or repeated

exposure if swallowed.

Harmful if swallowed.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical None known.

Unsuitable extinguishing

media

Specific hazards during fire

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Metal oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment.

Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

according to the Hazardous Products Regulations



Carbidopa / Levodopa Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 09/30/2023 50110-00023 Date of first issue: 01/23/2015 5.1

Methods and materials for containment and cleaning up Sweep up or vacuum up spillage and collect in suitable container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Static electricity may accumulate and ignite suspended dust Technical measures

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation Advice on safe handling Use only with adequate ventilation. Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Keep in properly labeled containers. Conditions for safe storage

Store locked up.

Store in accordance with the particular national regulations.

Materials to avoid Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives

Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type	Control parame-	Basis
		(Form of	ters / Permissible	

according to the Hazardous Products Regulations



Carbidopa / Levodopa Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.1 09/30/2023 50110-00023 Date of first issue: 01/23/2015

		exposure)	concentration	
Levodopa	59-92-7	TWA	500 μg/m3 (OEB 2)	Internal
Carbidopa	38821-49-7	TWA	2,000 μg/m3 (OEB 1)	Internal
Cellulose	9004-34-6	TWA	10 mg/m ³	CA AB OEL
		TWA (Total dust)	10 mg/m³	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m³	CA BC OEL
		TWAEV (to- tal dust)	10 mg/m³	CA QC OEL
		TWA	10 mg/m ³	ACGIH
Starch	9005-25-8	TWA	10 mg/m ³	CA AB OEL
		TWA (Total dust)	10 mg/m³	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m³	CA BC OEL
		TWAEV (to- tal dust)	10 mg/m³	CA QC OEL
		TWA	10 mg/m ³	ACGIH
Magnesium stearate	557-04-0	TWA	10 mg/m ³	CA AB OEL
		TWAEV	10 mg/m ³	CA QC OEL
		TWA (Inhal- able)	10 mg/m³	CA BC OEL
		TWA (Respirable)	3 mg/m³	CA BC OEL
		TWA (Inhalable particulate matter)	10 mg/m³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m³	ACGIH

Engineering measures : Use feasible engineering controls to minimize exposure to

compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

according to the Hazardous Products Regulations



Carbidopa / Levodopa Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 09/30/2023 50110-00023 Date of first issue: 01/23/2015 5.1

Eye protection Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection

Work uniform or laboratory coat.

Hygiene measures If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance powder

Color No data available

Odor odorless

Odor Threshold No data available

рΗ No data available

Melting point/freezing point No data available

Initial boiling point and boiling

range

No data available

No data available Flash point

No data available Evaporation rate

Flammability (solid, gas) May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure No data available

Relative vapor density No data available

according to the Hazardous Products Regulations



Carbidopa / Levodopa Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.1 09/30/2023 50110-00023 Date of first issue: 01/23/2015

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, dynamic : No data available

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Oxidizing agents

Incompatible materials :

Hazardous decomposition

products

: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Harmful if swallowed.

according to the Hazardous Products Regulations



Carbidopa / Levodopa Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.1 09/30/2023 50110-00023 Date of first issue: 01/23/2015

Product:

Acute oral toxicity : Acute toxicity estimate: 1,952 mg/kg

Method: Calculation method

Components:

Levodopa:

Acute oral toxicity : LD50 (Rat): 1,780 mg/kg

LD50 (Mouse): 2,363 mg/kg

Carbidopa:

Acute oral toxicity : LD50 (Rat): 4,810 mg/kg

LD50 (Mouse): 1,750 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 423

Assessment: The substance or mixture has no acute oral tox-

icity

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:

Carbidopa:

Species : Rabbit

Result : No skin irritation

according to the Hazardous Products Regulations



Carbidopa / Levodopa Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.1 09/30/2023 50110-00023 Date of first issue: 01/23/2015

Magnesium stearate:

Species : Rabbit

Result : No skin irritation

Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Carbidopa:

Species : Rabbit

Result : Mild eye irritation

Starch:

Species : Rabbit

Result : No eye irritation

Magnesium stearate:

Species : Rabbit

Result : No eye irritation

Remarks : Based on data from similar materials

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Levodopa:

Species : Guinea pig

Result : Not a skin sensitizer.

Carbidopa:

Remarks : No data available

Starch:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

Magnesium stearate:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig

according to the Hazardous Products Regulations



Carbidopa / Levodopa Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.1 09/30/2023 50110-00023 Date of first issue: 01/23/2015

Method : OECD Test Guideline 406

Result : negative

Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:

Levodopa:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration Test system: mouse lymphoma cells

Result: equivocal

Test Type: Micronucleus test

Test system: Chinese hamster lung cells

Result: positive

Test Type: sister chromatid exchange assay Test system: Chinese hamster lung cells

Result: positive

Carbidopa:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: positive

Test Type: In vitro mammalian cell gene mutation test

Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Starch:

according to the Hazardous Products Regulations



Carbidopa / Levodopa Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.1 09/30/2023 50110-00023 Date of first issue: 01/23/2015

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:

Levodopa:

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

Carbidopa:

Species : Rat
Application Route : Oral
Exposure time : 96 weeks

135 mg/kg body weight

Result : negative

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Levodopa:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 100 mg/kg body weight

according to the Hazardous Products Regulations



Carbidopa / Levodopa Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.1 09/30/2023 50110-00023 Date of first issue: 01/23/2015

Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Development

Species: Rabbit

Application Route: Oral

Developmental Toxicity: LOAEL: 125 mg/kg body weight Symptoms: Skeletal malformations., Visceral malformations.

Result: positive

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 10 mg/kg body weight

Test Type: Development

Species: Mouse Application Route: Oral

Developmental Toxicity: LOAEL: 500 mg/kg body weight

Symptoms: Effects on fetal development.

Result: positive

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

Carbidopa:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 120 mg/kg body weight Symptoms: Reduced body weight

Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Development

Species: Mouse Application Route: Oral

Developmental Toxicity: NOAEL: 120 mg/kg body weight

Result: No teratogenic effects.

Test Type: Development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 120 mg/kg body weight

Result: No teratogenic effects.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development

Species: Rat

according to the Hazardous Products Regulations



Carbidopa / Levodopa Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.1 09/30/2023 50110-00023 Date of first issue: 01/23/2015

Application Route: Ingestion

Result: negative

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the

reproduction/developmental toxicity screening test

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 422

Result: negative

Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

Components:

Levodopa:

Routes of exposure : Oral

Target Organs : Central nervous system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Levodopa:

Species : Rat

LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 106 Weeks

Target Organs : Central nervous system

Symptoms : Salivation

Species : Monkey
LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 22 Weeks

Target Organs : Central nervous system

according to the Hazardous Products Regulations



Carbidopa / Levodopa Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.1 09/30/2023 50110-00023 Date of first issue: 01/23/2015

Carbidopa:

Species : Rat
LOAEL : 25 mg/kg
Application Route : Oral
Exposure time : 96 Weeks

Remarks : No significant adverse effects were reported

Species : Monkey
NOAEL : 135 mg/kg
Application Route : Oral
Exposure time : 1 y

Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 5 mg/kg
LOAEL : 15 mg/kg
Application Route : Oral
Exposure time : 238 d

Symptoms : Diarrhea, Vomiting, Tremors

Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg

Application Route : Ingestion Exposure time : 90 Days

Starch:

Species : Rat

NOAEL : >= 2,000 mg/kg
Application Route : Skin contact
Exposure time : 28 Days

Method : OECD Test Guideline 410

Magnesium stearate:

Species : Rat

NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Levodopa:

Ingestion : Symptoms: Nausea, central nervous system effects, Drowsi-

ness

Carbidopa:

according to the Hazardous Products Regulations



Carbidopa / Levodopa Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 09/30/2023 50110-00023 Date of first issue: 01/23/2015 5.1

Ingestion Symptoms: involuntary movement

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Levodopa:

aquatic invertebrates

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 16 mg/l

Exposure time: 48 h

Carbidopa:

aquatic invertebrates

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 35.3 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Cellulose:

Toxicity to fish LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Magnesium stearate:

LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l Toxicity to fish

> Exposure time: 48 h Method: DIN 38412

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EL50 (Daphnia magna (Water flea)): > 1 mg/l

Exposure time: 47 h

Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

Toxicity to algae/aquatic

plants

EL50 (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms EC10 (Pseudomonas putida): > 100 mg/l

according to the Hazardous Products Regulations



Carbidopa / Levodopa Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.1 09/30/2023 50110-00023 Date of first issue: 01/23/2015

Exposure time: 16 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Magnesium stearate:

Biodegradability : Result: Not biodegradable

Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Levodopa:

Partition coefficient: n-

octanol/water

log Pow: -2.39

Magnesium stearate:

Partition coefficient: n-

octanol/water

: $\log Pow: > 4$

Mobility in soil
No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

according to the Hazardous Products Regulations



Carbidopa / Levodopa Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.1 09/30/2023 50110-00023 Date of first issue: 01/23/2015

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CA AB OEL : Canada. Alberta, Occupational Health and Safety Code (table

2: OEL)

CA BC OEL : Canada. British Columbia OEL

CA QC OEL : Québec. Regulation respecting occupational health and safe-

ty, Schedule 1, Part 1: Permissible exposure values for air-

borne contaminants

ACGIH / TWA : 8-hour, time-weighted average CA AB OEL / TWA : 8-hour Occupational exposure limit CA BC OEL / TWA : 8-hour time weighted average

CA QC OEL / TWAEV : Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median

according to the Hazardous Products Regulations



Carbidopa / Levodopa Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.1 09/30/2023 50110-00023 Date of first issue: 01/23/2015

Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to

compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 09/30/2023 Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8